Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28834071 | 1.00 | USP30 (0.51) | USP30BRD4PIM1PIM2BTK | |
| SCHEMBL29862617 | 1.00 | USP30 (0.51) | USP30BRD4PIM1PIM2BTK | |
| SCHEMBL29862707 | 1.00 | USP30 (0.51) | USP30BRD4PIM1PIM2BTK | |
| SCHEMBL28834225 | 1.00 | USP30 (0.51) | USP30BRD4PIM1PIM2BTK | |
| SCHEMBL23359862 | 0.94 | ALDH1A1 (0.49) | USP30BRD4BTKCNR1GPR119 | |
| SCHEMBL28834014 | 0.92 | USP30 (0.50) | USP30BRD4PIM1PIM2BTK | |
| SCHEMBL29933367 | 0.92 | USP30 (0.50) | USP30BRD4PIM1PIM2BTK | |
| SCHEMBL28834013 | 0.92 | USP30 (0.50) | USP30BRD4PIM1PIM2BTK | |
| SCHEMBL28834340 | 0.89 | USP30 (0.50) | USP30BRD4PIM1PIM2BTK | |
| SCHEMBL28834031 | 0.89 | USP30 (0.50) | USP30BRD4PIM1PIM2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |